SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): BGE-117

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: BioAge Labs

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 29, 2020

            Details:

            BioAge gets an exclusive worldwide license to develop and commercialize Taisho's clinical-stage Hypoxia-inducible factor-prolyl hydroxylase inhibitor, BGE-117, to treat multiple diseases of aging.